ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2270

Cardiovascular Disease: The Hidden Risk in Persons with Rheumatoid Arthritis

Karen Soikkeli1 and Glenn Ehresmann2, 1Graduate Nursing (Family Nurse Practitioner Program), Azusa Pacific University, Diamond Bar, CA, 2Rheumatology, Keck School of Medicine, University of Southern California-Los Angeles County Medical Center, Los Angeles, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Cardiovascular disease, Lipids, Rheumatoid arthritis (RA), risk assessment and risk management

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Epidemiology and Public Health Poster (ARHP)

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Despite the fact that patients with rheumatoid arthritis (RA) experience a 50-60% increased risk of developing cardiovascular disease (CVD), substantial gaps remain in the knowledge and application of risk prevention measures in RA patients. There is no standardized guideline or protocol for identification and management of the CVD risk in the RA population. The purpose of this study is to develop an algorithm based on current evidence with best practice measures for identification and management of CVD risk in the RA population.

Methods: An extensive review of literature was performed exploring and evaluating CVD impact in the RA population from 2009-2015 to identify current evidence based measures utilized in this population. Retrospective chart review of RA patients at a large community medical center identified the absence of consistent CVD risk screening. The American College of Cardiology/American Heart Association (ACC/AHA) guidelines and the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines were extrapolated to provide the foundation for the development of an algorithm for providers to reflect current best practice to improve patient outcome management.

Results: A review of literature reveals several barriers to the management of CVD risk in RA patients. No standardized guidelines exist relative to the CVD risk management in the RA patient, but European League Against Rheumatism (EULAR) has made recommendations.  Existing CVD risk scoring tools often underestimate risk, especially in RA. Computed tomography angiography (CTA) reveals higher plaque burden in asymptomatic RA patients without pre-existing CVD. Lipid knowledge remains incomplete with respect to epidemiology and pathogenesis of RA. Chart review of 35 RA patients at a community medical center revealed that only 40% contained any recorded lipid panel results; in the past year only 11.5% of the reviewed charts contained documentation of  lipid panel results.  An algorithm was developed to suggest improvements in CVD risk management in the RA population.  Increased collaboration between the primary care provider, rheumatologist, and nurse practitioner or physician assistant may enhance overall CVD management (see algorithm CVD Risk Management in RA Patients).

Conclusion: There is a paucity of identification and/or management of CVD in this population. An algorithm was developed in order to help providers identify aggressive CVD strategies, including lifestyle instruction as a standard of care in the RA population, thus improving the long term CVD outcomes. Further research is indicated and should be aimed at the development of CVD risk scoring tools specific for the RA patient, with concrete guidelines on the CVD risk in the RA population. Further studies involving the use of imaging and other alternate methods of risk identification are indicated.


Disclosure: K. Soikkeli, None; G. Ehresmann, Amgen, Abbvie, Genenteh, UCB, Takeda, Pfizer, Jansen, 8.

To cite this abstract in AMA style:

Soikkeli K, Ehresmann G. Cardiovascular Disease: The Hidden Risk in Persons with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/cardiovascular-disease-the-hidden-risk-in-persons-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-disease-the-hidden-risk-in-persons-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology